Genprex, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Genprex, Inc. (GNPX) on June 10, 2026. The filing addresses a critical corporate governance event regarding the company's listing status on The Nasdaq Capital Market. Genprex is a biopharmaceutical company focused on the development and commercialization of product candidates.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The only quantitative metric disclosed is the stock price performance: the company's common stock closed at less than $1.00 per share for the previous 30 consecutive business days, triggering a violation of Nasdaq Listing Rule 5550(a)(2).
Material Changes and Events
- Delisting Notice: On June 10, 2026, Genprex received a letter from the Nasdaq Listing Qualifications Staff determining that the company's securities will be delisted due to failure to maintain the $1.00 minimum bid price.
- Ineligibility for Compliance Period: The company was denied a standard 180-day compliance period because it effected a reverse stock split on October 21, 2025, within the prior one-year period.
- Immediate Action: The company intends to timely request a hearing before a Nasdaq Hearings Panel to stay the delisting action pending the hearing outcome.
Outlook, Risks, and Management Commentary
Management plans to take definitive steps to evidence compliance, which may include effecting another reverse stock split. However, the company explicitly states there is no assurance that the Hearings Panel will grant continued listing or that the company can maintain compliance within any extension period granted.
Identified Risks:
- Delisting Consequences: If delisted, the company faces potential material reduction in stock price, loss of market efficiencies, and loss of federal preemption of state securities laws.
- Capital Access: Delisting could impair the ability to raise capital on acceptable terms or at all.
- Reverse Stock Split Risks: Implementing a reverse split could negatively affect the stock price, reduce liquidity due to fewer outstanding shares, and result in a lower total market capitalization.
Investor Verification Checklist
- Verify the status of the requested hearing before the Nasdaq Hearings Panel and any subsequent rulings.
- Monitor the daily closing bid price of GNPX to determine if it reaches $1.00 for 10 consecutive business days (if an extension is granted).
- Review upcoming filings for announcements regarding a potential new reverse stock split.
- Assess the company's cash runway and liquidity position in the context of potential delisting and restricted capital market access.